IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

September 29, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease. The new site, Ichor Research, located in Syracuse, New York, is led by Principal Investigator Dr. Karl F. Hafner, M.D. Dr. Hafner brings years of experience in clinical research and patient care, particularly in the field...

Read more

Faro Wins CDISC 2025 AI Innovation Challenge for Protocol Library Solution

September 29, 2025 7:00 AM

Faro, the pioneer in AI-powered clinical protocol design, has been named the winner of the prestigious CDISC 2025 AI Innovation Challenge for its groundbreaking solution in the Protocol Library - Building USDM-Centric Repositories from Existing Protocols category.Faro was selected from a highly competitive group of entries to win the award, leveraging its AI system to digitize existing protocols and building a powerful library of past studies...

Read more

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

September 26, 2025 8:45 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.As part of the segment, Mr. Berman discussed the Company's recent news announcing it filed a request for supervisory appeal of the not-approvable letter...

Read more

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial

September 26, 2025 2:20 AM

Pentixapharm AG (Frankfurt Prime Standard:PTP), an advanced clinical-stage biotech, developing novel radiopharmaceuticals, today announced that its CXCR4-targeting radiolabeled candidate PentixaTher has advanced to the fourth dose level in the investigator-initiated PENTILULA Phase 1/2 study in acute myeloid leukemia (AML).Based on favorable safety findings at the third dose level of 7.5 GBq, the investigator-initiated trial received approval...

Read more

ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer

September 25, 2025 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that Dr. Paul Larson will be joining the company as Chief Medical Officer starting in January 2026. Dr. Larson has a long history of working with ClearPoint Neuro as an advisor, especially supporting education and product development efforts related to cell and gene...

Read more

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

September 25, 2025 8:30 AM

Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today announced advancement of its biomarker discovery preclinical program in Parkinson's Disease. The initiative leverages BioSymetrics' proprietary Augusta Platform to unlock novel treatment pathways in one of the world's fastest-growing neurological markets. The company is actively positioning the program for strategic...

Read more

Bora Biologics to Manufacture NYPOZI(TM) at San Diego Facility in Partnership with InvaGen Pharmaceuticals, a Cipla Group Company

September 25, 2025 7:00 AM

Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics, proudly announces its partnership with InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, for the manufacture of NYPOZI™ (biosimilar to Neupogen®) at its FDA-registered facility in San Diego, California.This collaboration signifies a major advancement in the biopharmaceutical sector, as NYPOZI™ is set to become...

Read more

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

September 24, 2025 4:50 PM

Lunai Bioworks, Inc. (Nasdaq:RENB) ("Lunai Bioworks" or the "Company"), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that the Company's Board of Directors has approved a 10:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on September 30, 2025. The Company's Common Stock...

Read more

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

September 24, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's disease. The data demonstrate that TGR-63 extends its therapeutic potential beyond previously reported effects on beta-amyloid (Aβ) pathology by also inhibiting tau protein aggregation, another key hallmark of Alzheimer's. "These results underscore the potential of TGR-63 as a...

Read more

Ben Lamm's Astromech Secures $30 Million to Advance AI-Biotechnology Innovation

September 23, 2025 1:40 PM

Entrepreneur Ben Lamm, co-founder of Colossal Biosciences, has announced the successful close of a $30 million funding round for his new company, Astromech, highlighting growing investor confidence in the convergence of artificial intelligence and biotechnology. Astromech is incorporated in Delaware and is currently operating in stealth mode. The company is developing proprietary AI technologies aimed at advancing research and development in...

Read more

Lifeloc to Present at Emerging Growth Conference on September 25, 2025

September 23, 2025 1:30 PM

Lifeloc Technologies, Inc. (OTC:LCTC), a U.S.-based manufacturer of precision breath alcohol and drug detection devices, announced today that it will present at the Emerging Growth Conference on Thursday, September 25, 2025.This live, interactive virtual event will feature a presentation by Dr. Wayne Willkomm, Lifeloc's Chief Executive Officer. Dr. Willkomm will provide an overview of Lifeloc's current operations and share an update on the...

Read more

NDT Pharmaceuticals' Good Salt(TM) Life Subsidiary Unveils Scalable Antimicrobial Platform to Drive Health, Safety, and Sustainability Across Global Markets

September 23, 2025 9:10 AM

Good Salt™ Life, Inc., a wholly owned subsidiary of NDT Pharmaceuticals Inc. (OTCID:NDTP) ("NDTP" or the "Company"), today shared insight into its strategic initiative designed to build value through investments in sustainable, science-driven health and wellness brands that protect people, pets, and the planet. Good Salt Life targets the $148 billion global biosafety market with a vertically integrated approach that combines proprietary hardware...

Read more

Announcement from the Annual General Meeting in Biovica International AB

September 23, 2025 6:18 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 23 September 2025 and the following resolutions were passed by the meeting.Adoption of the income statement and balance sheetThe annual general meeting resolved to adopt Biovica's income statement and balance sheet as well as the consolidated income statement and consolidated balance...

Read more

AbTherx and Dragonfly Therapeutics Expand Antibody Discovery Partnership

September 23, 2025 6:00 AM

AbTherx, a biotechnology company pioneering technologies that accelerate antibody discovery, today announced an expansion of its ongoing partnership with Dragonfly Therapeutics (Dragonfly) following a successful multi-target pilot study comparing transgenic platforms.The evaluation reinforces AbTherx's approach, which combines an industry‑leading track record in transgenic technology development (13 marketed therapeutics) with evolutionary...

Read more

Vicore Announces Presentations at the European Respiratory Society Congress 2025

September 23, 2025 2:15 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the European Respiratory Society (ERS) Congress 2025, taking place in Amsterdam, the Netherlands, from September 27 - October 1, 2025.Vicore will present new findings from the 36-week Phase 2a AIR trial of buloxibutid in idiopathic pulmonary fibrosis (IPF),...

Read more

Chef Rasmus Munk Joins Global Consortium Turning CO2 Into Tasty Foods

September 23, 2025 1:00 AM

Will air-to-table be the next big thing? Alchemist chef Rasmus Munk's food innovation center Spora plays a key role in a global project to create delicious foods from protein derived from CO₂."We are extremely proud that two of the world's largest foundations have chosen us as a partner in this ambitious project with the potential to feed more than a billion people every year," says Rasmus Munk, voted Best Chef in the World 2024 by The Best Chef...

Read more

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

September 22, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. This milestone marks a significant step in advancing IGC-AD1, the Company's proprietary formulation that combines low concentrations of...

Read more

Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer

September 22, 2025 3:00 AM

Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced final results from the OPTIMIZE-1 trial evaluating its lead asset, mitazalimab, in combination with mFOLFIRINOX chemotherapy in patients with previously untreated metastatic pancreatic cancer.The OPTIMIZE-1 study has consistently demonstrated promising clinical activity...

Read more

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

September 19, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that it has received notifications from option holders to exercise 2015D options over 111,000 ordinary shares in the Company at an exercise price of EUR 1.09 per share, raising gross proceeds of approximately EUR 120,990 under the Company's 2015 Option Plan (" New Ordinary Shares ")....

Read more

Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise

September 18, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostics and disease management tools, today announced that it has received equity capital totaling $3.06 million from existing and new investors. The company has entered into a securities purchase agreement dated September 18, 2025, pursuant to which the Company has sold...

Read more